China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is being adjusted to focus on long-term development; 2) channel expansion is being further promoted, production capacity is continuously strengthened, and core competitiveness is continuously consolidated; 3) the intention to control Huilun Pharmaceutical through equity acquisition to deepen the small molecule chemical business layout, which is expected to enhance the company's performance. (Mainichi Keizai Shimbun)
中邮证券4月12日发布研报称，给予新天药业（002873.SZ）买入评级。评级理由主要包括：1）公司业绩阶段性承压，调整费用投入聚焦长远发展；2）渠道拓展深入推进，生产能力不断加强，持续夯实核心竞争力；3）拟通过收购股权控制汇伦医药，深化小分子化药业务布局，有望增厚公司业绩。（每日经济新闻）
China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.